Sleep medicines and supplements: questions before using them

Recurring difficulty initiating or maintaining sleep despite an opportunity to sleep is a reason to discuss insomnia with a clinician. NHLBI describes CBT-I as a structured treatment that is usually recommended first for long-term insomnia. It can be delivered in person, by phone or online. A product that makes someone drowsy may not address the habits and thoughts that keep insomnia going.

Breathing pauses, gasping and loud snoring call for an apnea evaluation rather than a general sleep aid. A body-clock mismatch may require a timing-oriented plan. Persistent sleepiness or other unusual events may need a specialist assessment. One sedative purchase should not obscure a different untreated disorder.

Prescription insomnia medicines have different purposes and intended durations. FDA highlights eszopiclone, zaleplon and zolpidem, often called Z-drugs, for a boxed warning about rare but serious complex sleep behaviors, including sleepwalking or sleep driving. Next-day impairment can occur even when someone feels awake. FDA advises avoiding alcohol and other sleep drugs with these products. After a complex sleep behavior, FDA says to stop taking the Z-drug and contact a healthcare professional immediately.

Benzodiazepines are another drug class, with FDA warnings about misuse, addiction, physical dependence and withdrawal. Those warnings do not mean every insomnia prescription is a benzodiazepine. Ask the prescriber what the chosen medicine is expected to change, how its effects will be assessed, and when to review continuation or stopping. For benzodiazepines, do not stop abruptly; discuss a safe stopping plan with the prescriber. The FDA stop instruction after a complex sleep behavior on a Z-drug is a separate, event-specific warning.

Melatonin is a hormone involved in circadian timing. NCCIH reports possible benefit for some timing-related concerns such as jet lag or delayed sleep phase, while chronic-insomnia guidelines do not find strong enough evidence to recommend it for that condition. Short-term use appears relatively safe for many adults, but long-term safety information is limited. Interactions matter, including for people taking blood thinners or with epilepsy.

In the United States, FDA does not approve dietary supplements for safety and effectiveness before marketing. Product contents can differ from the label, and “natural” does not establish safety. Ask whether an over-the-counter sleep product contains an antihistamine or other active ingredient, whether it might compound drowsiness, and whether it fits your health history. A pharmacist can help reconcile a complete product list.

An insomnia medicine or supplement is not an OSA airway treatment. If snoring, gasping or witnessed pauses are present, ask for an appropriate evaluation. A person taking PAP should report persistent symptoms or difficulty using the device, because the response may call for a fit, pressure or follow-up change rather than another sleep aid.

Zepbound is a separate prescription medicine with a narrow FDA-labeled OSA indication for adults with obesity and moderate to severe obstructive apnea. It is not a general sedative or a routine insomnia supplement. Its own contraindications, warnings, clinical monitoring and cost questions belong in an OSA care discussion.

Ask: What condition are we treating? What measurable improvement should I expect, and when will we reassess? What are the exact drug or supplement ingredients and interaction concerns? Could I be impaired at work or while driving the next day? What should I do if it does not help or causes an adverse effect? These questions make the choice specific to the person and prevent several sedating products from being layered without review.

Tell the clinician about pregnancy or nursing, breathing symptoms, prior complex sleep behaviors, alcohol use, all current medicines and supplements, and any plan to stop a long-used prescription. Keep the exact product package or medication list. Do not use a marketing claim, a research peptide listing or another person’s experience as a substitute for that review.